Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial.

Trials · 2015 · PMC4570043 · PMID 26374625

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In addition, although recent head-to-head comparison between BP-BES with CoCr-EES showed comparable clinical outcomes up to 2 years of follow-up (NEXT trial) or up to 3 years of follow-up (COMPARE II trial), the COMPARE II trials showed a trend showing higher risk of ST in BP-BES than EES [ 18 – 20 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.